We are a group of committed shareholders, including the company’s co-founders, united to realign OSE Immunotherapeutics on a responsible, ambitious, and sustainable course.
In response to what we see as a risky and value-destructive strategy, we propose a new governance and a clear plan:
Paris (France), on June 20, 2025. Dear shareholders, We, Mrs. Dominique Costantini, Mr. Emile Loria and Mr. Alexis Peyroles, hereby inform the shareholders of OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:…
Lire plus
Dear OSE Immunotherapeutics Shareholders, As co-founders and former directors of OSE Immunotherapeutics,…
In order to explain the reasons for the 10 draft resolutions which…
Lionel Labourdette, PhD Données de la phase de maintenance : des signes…
English
Français
